ZYNE Zynerba Pharmaceuticals Inc.

4.25
-0.11  -3%
Previous Close 4.36
Open 4.34
Price To Book 1.17
Market Cap 74914210
Shares 17,626,873
Volume 178,229
Short Ratio
Av. Daily Volume 305,699

SEC filingsSee all SEC filings

  1. 8-K - Current report 181231522
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168321
  3. 8-K - Current report 181168079
  4. 8-K - Current report 181095852
  5. 8-K - Current report 181053905

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial failed to meet target blood levels. Company to focus on ZYN002.
ZYN001
Healthy volunteers
Development to be discontinued - noted January 2018.
ZYN001
Fibromyalgia
Development to be discontinued - noted January 2018.
ZYN001
Peripheral Neuropathic Pain (PNP)
Pivotal trial initiation announced July 9, 2018 with top-line data due 2H 2019.
ZYN002
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
ZYN002 - STOP
Osteoarthritis
Phase 2 data released August 7, 2017 - endpoints not met. Phase 2b trial to be initiated 2H 2018.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2 open label trial initiation announced April 10, 2018. Top-line data due 2019.
Phase 2 BELIEVE 1
Developmental and Epileptic Encephalopathies (DEE)

Latest News

  1. The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
  2. Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
  3. When Will Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Become Profitable?
  4. Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape
  5. Opioid Alternatives Could Make Investors Major Gains
  6. Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
  7. Sell-Side Analysts See Upside Potential In Zynerba
  8. Zynerba: 3Q Earnings Snapshot
  9. Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
  10. Reading Filings to Predict Future Events
  11. Short Sellers Are Making Huge Profits In Cannabis Stocks
  12. Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In?
  13. Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
  14. Beverage Giants Buying Into The Cannabis Boom
  15. 2 Marijuana Biotechs to Watch
  16. The Hottest CBD Stocks
  17. Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
  18. Cantor Fitzgerald's 7 Buys For 7 Biotechs
  19. Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

SEC Filings

  1. 8-K - Current report 181231522
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168321
  3. 8-K - Current report 181168079
  4. 8-K - Current report 181095852
  5. 8-K - Current report 181053905
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986726
  7. 8-K - Current report 18986568
  8. 8-K - Current report 18963179
  9. 424B5 - Prospectus [Rule 424(b)(5)] 18963162
  10. 8-K - Current report 18960545